03:21 PM EDT, 09/09/2024 (MT Newswires) -- Phanes Therapeutics said Monday it has dosed the first patient in a trial of PT886 in combination with chemotherapy.

PT886 is an antibody that is also the subject of a clinical collaboration with Merck's ( MRK ) cancer therapy Keytruda.

Phanes said PT886 dosing was previously completed in two patients, one for first-line treatment of pancreatic cancers and another for second-line treatment of gastric, gastroesophageal junction cancers.

Price: 115.36, Change: -2.48, Percent Change: -2.11